An investigation on behalf of investors in Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares over potential wrongdoing at Halozyme Therapeutics, Inc. was announced and NASDAQ:HALO stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 03/27/2018 -- An investigation was announced for investors in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) over potential breaches of fiduciary duties by certain officers and directors at Halozyme Therapeutics.
Investors who purchased shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554.
Halozyme Therapeutics, Inc. reported that its annual Total Revenue rose from $146.69 million in 2016 to $316.61 million in 2017 and that its Net Loss of $103.02 million in 2016 turned into a Net Income of $62.97 million in 2017.
O January 16, 2018, an abstract detailing a Phase IB/II randomized study of Halozyme's drug PEGPH20 as a treatment for pancreatic cancer in combination with the cancer drug mFFOX was published in connection with a scheduled presentation at the 2018 Gastrointestinal Cancers Symposium. The abstract's authors concluded that the "addition of PEGPH20 to mFFOX is not recommended for further study and appears to be detrimental" after noting that patients who used the combination experienced higher levels of diarrhea, fatigue, nausea, vomiting, and more than those who used mFFOX as a monotherapy. Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) declined to as low as $16.06 per share on February 9, 2018.
On March 26, 2018, NASDAQ:HALO shares closed at $19.43 per share.
Those who purchased shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels